Health TrialsbyHealthPanel

Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study

ConditionsCovid19SARS-CoV InfectionTransplantation Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent

Disqualifiers

age under 18 years

Trial population

all patients who underwent solid organ or hematopoietic transplantation at UZ Leuven and who give informed consent

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • SARS-CoV-2 IgG

    Diagnostic test

    Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies

Treatment groups

2,000 Participants
are divided into 3 treatment groups
Group A: Transplanted patients1 intervention
Group B: Transplanted patients with past SARS-CoV-2 infection1 intervention
Group C: Transplanted patients without past SARS-CoV-2 infection1 intervention

Trial outcomes

Primary outcomes

1

Prevalence and risk-factors for SARS-CoV-2 infection

Prevalence and risk-factors for SARS-CoV-2 infection

Time frame
inclusion during 4 months
2

Prevalence and risk-factors for COVID-19

Prevalence and risk-factors for COVID-19

Time frame
inclusion during 4 months

Secondary outcomes

1

Durability of IgG positivity

Durability of IgG positivity/immunity

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

KU Leuven

Collaborator

Hasselt University

Collaborator

Ziekenhuis Oost-Limburg

Collaborator

Jessa Hospital

Collaborator

Source ClinicalTrials.gov
Apply now